InventisBio
Shanghai
China
About InventisBio
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas. Prior to the Series B financing, the company received investment from angel investors led by Beautiful Mind Investment Management Ltd in 2015 and Series A financing led by Lilly Asia Venture and SinoPharm Capital in May 2016, totaling USD11 million.LEADERSHIP:
Founder and CEO: Yaolin Wang
6 articles about InventisBio
-
Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.
-
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
4/11/2022
InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients.
-
InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures
9/27/2020
InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds.
-
Clinical Stage Biotech Company InventisBio Inc. Closes $70 Million USD Series C Financing
3/11/2019
InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.
-
InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer
12/28/2018
InventisBio (Shanghai) (hereinafter referred to as "InventisBio") announced today that it has signed a "Collaboration Agreement" with Betta Pharma (hereinafter referred to as "Betta Pharma")
-
InventisBio Raises USD19 Million in Series B Financing Led By OrbiMed
5/31/2017